1. Home
  2. THO vs NAMS Comparison

THO vs NAMS Comparison

Compare THO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Thor Industries Inc.

THO

Thor Industries Inc.

HOLD

Current Price

$75.17

Market Cap

4.1B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$31.78

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THO
NAMS
Founded
1980
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.1B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
THO
NAMS
Price
$75.17
$31.78
Analyst Decision
Buy
Strong Buy
Analyst Count
11
8
Target Price
$111.75
$46.75
AVG Volume (30 Days)
758.3K
977.5K
Earning Date
06-03-2026
05-06-2026
Dividend Yield
2.67%
N/A
EPS Growth
N/A
N/A
EPS
2.59
N/A
Revenue
$9,579,490,000.00
N/A
Revenue This Year
$1.21
$17.96
Revenue Next Year
$5.17
$540.65
P/E Ratio
$29.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$69.71
$21.14
52 Week High
$122.83
$42.21

Technical Indicators

Market Signals
Indicator
THO
NAMS
Relative Strength Index (RSI) 51.00 42.75
Support Level $74.45 $29.23
Resistance Level $82.46 $31.72
Average True Range (ATR) 2.95 1.86
MACD 0.20 -0.38
Stochastic Oscillator 60.72 13.64

Price Performance

Historical Comparison
THO
NAMS

About THO Thor Industries Inc.

Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business as it accounted for less than 10% of fiscal 2025 total sales. In fiscal 2025, the company wholesaled 181,388 units and generated $9.6 billion in revenue.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: